{
  "run_id": "688eab76-7005-495c-a8ea-88018c75729e",
  "prompt_variant_id": "fa0685be-90ff-41f5-84e8-95e3cd2d2818",
  "api_config_name": "model_deepseek_coder",
  "test_case_id": "breast_cancer_test",
  "start_time": "2025-08-29T04:07:05.407658",
  "end_time": "2025-08-29T04:10:01.738903",
  "duration_ms": 176329.8008441925,
  "success": true,
  "error_message": "",
  "entities_extracted": 25,
  "entities_mapped": 24,
  "extraction_completeness": 1.5625,
  "mapping_accuracy": 0.5,
  "precision": 0.5769230769230769,
  "recall": 0.9375,
  "f1_score": 0.7142857142857143,
  "compliance_score": 1.0,
  "token_usage": 6179,
  "extracted_entities": [
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 1.0,
      "source_context": {
        "section": "Conditions",
        "position": 0,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 1.0,
      "source_context": {
        "section": "Conditions",
        "position": 25,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Histologically confirmed HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "30-80",
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "55-68",
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Measurable disease per RECIST 1.1",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "82-110",
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "RECIST 1.1",
      "type": "procedure",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "100-110",
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "ECOG performance status 0-1",
      "type": "demographic",
      "attributes": {
        "status": "positive",
        "value": "0-1",
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "112-135",
        "context_sentence": "ECOG performance status 0-1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Adequate organ function",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "137-158",
        "context_sentence": "Adequate organ function",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Prior treatment with Trastuzumab Deruxtecan",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "180-220",
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Trastuzumab Deruxtecan",
      "type": "medication",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "200-220",
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Active brain metastases",
      "type": "condition",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "222-243",
        "context_sentence": "Active brain metastases",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Pregnancy",
      "type": "condition",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "245-254",
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "breastfeeding",
      "type": "condition",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "258-270",
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-targeted therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": 20,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefSummary",
        "position": 60,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefSummary",
        "position": 75,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "progressed",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": 95,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "trastuzumab-based therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": 110,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefTitle",
        "position": "20-45",
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "officialTitle",
        "position": "30-65",
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefTitle",
        "position": "20-33",
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "officialTitle",
        "position": "30-43",
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Novel Therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "future"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefTitle",
        "position": "10-22",
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Novel Targeted Therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "future"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "officialTitle",
        "position": "15-35",
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Phase III",
      "type": "procedure",
      "attributes": {
        "status": "positive",
        "value": "III",
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "officialTitle",
        "position": "2-10",
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    }
  ],
  "mcode_mappings": [
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 0",
      "mapping_rationale": "Direct mapping to cancer condition with HER2 biomarker status",
      "id": "62b2588e-fe17-4368-9f2a-213a4755b01a",
      "llm_source_text_fragment": "Entity index 0",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 1",
      "mapping_rationale": "Direct mapping to metastatic cancer condition",
      "id": "c44d7c2f-3792-4b74-a2a0-302ad179008e",
      "llm_source_text_fragment": "Entity index 1",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 2",
      "mapping_rationale": "Combined cancer condition with biomarker and metastatic status",
      "id": "f0bafaff-38e5-40a4-a50a-c6f4f9867df1",
      "llm_source_text_fragment": "Entity index 2",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 3",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant observation",
      "id": "bfc16577-6a5e-4f89-8319-4e8b1e684316",
      "llm_source_text_fragment": "Entity index 3",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "CancerDiseaseStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerdiseasestatus",
        "display": "CancerDiseaseStatus"
      },
      "value": "active",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 4",
      "mapping_rationale": "Measurable disease implies active disease status",
      "id": "6923de5c-4140-4eca-a835-398659444570",
      "llm_source_text_fragment": "Entity index 4",
      "source_references": []
    },
    {
      "resourceType": "Procedure",
      "Mcode_element": "CancerRelatedProcedure",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedprocedure",
        "display": "CancerRelatedProcedure"
      },
      "value": "RECIST 1.1 assessment",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 5",
      "mapping_rationale": "RECIST 1.1 is a cancer response assessment procedure",
      "id": "02fa297d-7ba9-4fdf-bf1e-7a2febf18668",
      "llm_source_text_fragment": "Entity index 5",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "ECOGPerformanceStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "ecogperformancestatus",
        "display": "ECOGPerformanceStatus"
      },
      "value": "0-1",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 6",
      "mapping_rationale": "Direct mapping to ECOG performance status score",
      "id": "67db0d47-83be-4444-88c1-cede39848656",
      "llm_source_text_fragment": "Entity index 6",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "adequate organ function",
      "mapping_confidence": 0.7,
      "source_text_fragment": "Entity index 7",
      "mapping_rationale": "General condition related to cancer treatment eligibility",
      "id": "6d21b293-1364-48e8-934e-ca5e009ecfee",
      "llm_source_text_fragment": "Entity index 7",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 8",
      "mapping_rationale": "Cancer medication with negative status indicating exclusion",
      "id": "95017845-b632-4295-a54f-06013aafce8c",
      "llm_source_text_fragment": "Entity index 8",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 9",
      "mapping_rationale": "Direct mapping to cancer-related medication",
      "id": "5bf6692d-a5b2-4592-b1ad-7ce10cf6467e",
      "llm_source_text_fragment": "Entity index 9",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "brain metastases",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 10",
      "mapping_rationale": "Metastatic cancer condition with negative status for exclusion",
      "id": "4a6cad93-8819-4833-8ce7-2300e27c95cf",
      "llm_source_text_fragment": "Entity index 10",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "pregnancy",
      "mapping_confidence": 0.6,
      "source_text_fragment": "Entity index 11",
      "mapping_rationale": "General medical condition affecting cancer treatment eligibility",
      "id": "5ce44209-34d4-422e-9d3b-b77aa2657b21",
      "llm_source_text_fragment": "Entity index 11",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "breastfeeding",
      "mapping_confidence": 0.6,
      "source_text_fragment": "Entity index 12",
      "mapping_rationale": "General medical condition affecting cancer treatment eligibility",
      "id": "6063bd5a-9fbb-4214-84b0-dbc06e7c6f75",
      "llm_source_text_fragment": "Entity index 12",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "HER2-targeted therapy",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 13",
      "mapping_rationale": "Class of cancer medications targeting HER2",
      "id": "96194b7d-9731-46ea-9a4c-38bdf5b73a50",
      "llm_source_text_fragment": "Entity index 13",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 14",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant observation",
      "id": "43724525-6a0d-4de7-8231-f23a7a346485",
      "llm_source_text_fragment": "Entity index 14",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 15",
      "mapping_rationale": "Direct mapping to metastatic cancer condition",
      "id": "83cd7fab-08d9-45d9-881d-402f2bdf922d",
      "llm_source_text_fragment": "Entity index 15",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "CancerDiseaseStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerdiseasestatus",
        "display": "CancerDiseaseStatus"
      },
      "value": "progression",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 16",
      "mapping_rationale": "Disease progression status indicating treatment failure",
      "id": "c9858f98-3fc4-456e-bbca-4198012294e1",
      "llm_source_text_fragment": "Entity index 16",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "trastuzumab-based therapy",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 17",
      "mapping_rationale": "Class of cancer medications including trastuzumab",
      "id": "7a1238e2-d693-4916-90b2-01b365e38cb7",
      "llm_source_text_fragment": "Entity index 17",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 18",
      "mapping_rationale": "Direct mapping to cancer condition with biomarker status",
      "id": "d95d20bc-52cb-4449-ba5b-f4c34d13163c",
      "llm_source_text_fragment": "Entity index 18",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 19",
      "mapping_rationale": "Combined cancer condition with biomarker and metastatic status",
      "id": "e21a71d1-eeaf-41c4-a66a-052054498eb0",
      "llm_source_text_fragment": "Entity index 19",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 20",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant observation",
      "id": "91a798e7-7930-4aa2-9d9f-0de468a2354d",
      "llm_source_text_fragment": "Entity index 20",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 21",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant observation",
      "id": "3ab5e6dc-9a4d-4943-b723-7a7595457154",
      "llm_source_text_fragment": "Entity index 21",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Novel Therapy",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 22",
      "mapping_rationale": "Experimental cancer medication being studied",
      "id": "34118ef8-e466-4f87-8a55-85462323576c",
      "llm_source_text_fragment": "Entity index 22",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Novel Targeted Therapy",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 23",
      "mapping_rationale": "Experimental targeted cancer medication being studied",
      "id": "7f5629b1-1f99-4bde-a393-eec6b77b69d7",
      "llm_source_text_fragment": "Entity index 23",
      "source_references": []
    }
  ],
  "validation_results": {
    "valid": true,
    "errors": [],
    "warnings": [],
    "compliance_score": 1.0
  }
}